Can the CSL (ASX:CSL) share price crack the $300 mark in 2022?

Can CSL's shares climb beyond $300?

| More on:
A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have fallen heavily this year and trade notably lower than their 52-week high
  • A result from a key rival this week hasn't helped sentiment
  • Nevertheless, two brokers remain confident CSL's shares can trade beyond $300

The CSL Limited (ASX: CSL) share price is on course to end the week in the red.

In afternoon trade, the biotherapeutics giant's shares are down 0.5% to $255.80.

This means the CSL share price is down over 13% in 2022 and 20% from its 52-week high of $319.78.

Why is the CSL share price falling today?

The weakness in the CSL share price on Friday appears to have been driven by a mixed result from one of its rivals, Takeda.

While the Japanese biotech giant reported strong immunoglobulin sales for the third quarter, it also revealed a sizeable reduction in plasma collections.

Concerns about plasma collection headwinds and the impact they could have on CSL's margins have been weighing on sentiment during the pandemic. Based on Takeda's update, it appears as though these headwinds have yet to ease.

Can its shares get back above $300 in 2022?

Until the aforementioned plasma collection headwinds ease, the CSL share price is likely to remain out of favour with investors.

Though, when these headwinds do finally ease and investor sentiment improves, a number of brokers believe its shares could be trading at materially higher levels and well beyond the $300 mark.

For example, both Citi and Morgans have the equivalent of buy ratings on its shares with price targets of $340.00 and $334.70, respectively. These price targets imply potential upside of 30%+ over the next 12 months.

In respect to Morgans, it feels FY 2022 is a transitional year but remains very positive on the long term.

The broker commented: "We view CSL as a core holding and best positioned among its peers to meet growing patient demand, but the near term remains challenged, with timing uncertainty around a full recovery in plasma collections and increasing costs."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Broker looking at the share price.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Broker Notes

Guess which ASX 200 share offers 12% upside and a 4% dividend yield

Bell Potter just slapped a buy rating on this stock.

Read more »

A man leaps from a stack of gold coins to the next, each one higher than the last.
Broker Notes

Qantas or Telstra share price: Which will climb higher in 2024?

Let's see what top broker Goldman Sachs has to say about these ASX blue-chip stocks.

Read more »

A woman smiles as she sits on the bus using her phone and listening to music through headphones.
Small Cap Shares

3 small-cap ASX shares with 'long runways for growth'

DNR's Sam Twidale reckons investors could do worse than buy these guys for the long run.

Read more »

Woman using laptop for job search
Investing Strategies

2 ASX 200 shares to buy for 'strong growth' at decent prices right now

Searching for a bargain? Here's a pair that Catapult's Dylan Evans has his eyes on at the moment.

Read more »

A Paladin Energy miner wearing a hard hat and protective gear stands in front of a large mining truck and smiles to the camera.
Energy Shares

Uranium is set to boom, and this is the 'premium' ASX stock to buy

Shaw and Partners' Jed Richards reckons these are the shares to buy for the nuclear energy theme.

Read more »

female in hard hat crosses fingers
Investing Strategies

The ASX 200 stock that could get second time lucky

These shares have failed to impress in 2024, but many experts believe it's a bargain buy.

Read more »